<DOC>
	<DOCNO>NCT02655666</DOCNO>
	<brief_summary>The purpose study observe/ collect clinical data , subject user ' feedback , device data well understand real-life usage acceptance 722 Pump type 1 diabetes subject , &lt; 18 year age , role insulin pump therapy Qingdao , China .</brief_summary>
	<brief_title>Qingdao : Insulin Pump Follow-Up Program</brief_title>
	<detailed_description>This prospective , multi-center , non-randomized noninterventional post-market release study . Subjects participate 2 phase phase require subject use continuous subcutaneous insulin infusion ( CSII ) pump course study . During study , subject parent legal guardian train wear glucose sensor abdominal area 3 day transmit real-time ( RT ) data pump . The duration study phase approximately 6 month .</detailed_description>
	<criteria>Subject age &lt; 18 year time screen Subject clinical diagnosis type 1 diabetes Subject willing perform require sensor calibration Subject willing wear Medtronic MiniMed ParadigmÂ® REAL Time System continuously throughout study Subject participant Qingdao project . Subject actively participate investigational study ( drug device ) wherein he/she receive diabetes treatment investigational study drug investigational study device last 2 week Subject know hypersensitivity insulin insulin infusion set ( include tape ) Subject use insulin pump and/or real time CGM/sensor within 90 day screen visit 10 day outpatient setting : For example , subject use insulin pump and/or real time CGM/sensor inpatient set still eligible enrollment . For example , subject use insulin pump and/or real time CGM/sensor 8 day outpatient set within 90 day screen visit still eligible enrollment . For example , subject worn insulin pump and/or real time CGM/sensor 3 month outpatient set year screen visit still eligible enrollment Subject treat drug know effect BG within 8 week enrollment diabetes medication insulin oral antidiabetic agent . Subject systemic disease medical condition find screening may interfere safety patient efficacy study treatment , opinion Investigator , may preclude him/her participate study . Subject treat hyperthyroidism time screen Subject take oral , injectable , IV steroid within 8 week time screen visit , plan take oral , injectable , IV steroids course study Subject currently abuse alcohol9 . Any condition either Investigator believe would interfere study participation evaluation result .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>